Did you know?
The dual bronchodilator combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered once daily in a single inhaler has demonstrated superior lung function improvements over either monocomponent alone in the large Phase 3 TONADO program (n=5,162 patients). Both LAMA/LABA doses significantly improved FEV1 AUC0–3 and trough FEV1 vs. the individual components in patients with moderate to very severe COPD, and the 5/5 μg dose also produced statistically significant improvements in St George’s Respiratory Questionnaire total score.
From a managed care perspective, how do single-inhaler dual-bronchodilator regimens affect medication adherence and simplification of COPD therapy versus multiple-device regimens?
-
Swati DesaiYesterdayMakes a huge difference in compliance and hence improvement in symptoms with combined inhalers
-
JOEL WASHINSKY2dIt will increase compliance due to a simpler regimen.
-
Kevin Glass4dIn my experience anything that simplifies a treatment regimen like dual and triple therapy in a single inhaler device will increase compliance and medication adherence.
-
SHABNAM SACHDEVA1wDual bronchodilators with LAMA/LABA combination such as ANORO are well covered under most insurance plans , improve lung function and decrease exacerbations.
-
Kristina Cipparrone1wIt improves compliance as there is only one inhaler to remember to take. Also, there is only one copay which helps with cost.
-
SACHINKUMAR PANCHAL1wMy opinion a single-inhaler combination can improve convenience, help patients stay on treatment, and may reduce healthcare costs by keeping COPD better controlled.